Erivedge Development Timeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A timeline chronicling the development history of Genentech’s vismodegib.
You may also be interested in...
Erivedge Efficacy Overcomes Limitations Of Single-Arm Study
Response rates of 30%-43% and a 7.6-month median duration of response were sufficiently clinically meaningful to allow FDA approval of Genentech’s basal cell carcinoma treatment on the basis of a non-randomized study.
Erivedge Reviewers
FDA staff that participated in the review of Genentech’s basal cell carcinoma treatment vismodegib.
Will The New Math Of Oncology Drug Review Times Carry Over Into PDUFA V?
The Office of Hematology and Oncology Products originally targeted a four-month review goal for vismodegib, but review staff deemed such a compressed timeline not feasible.